{"id":"cisplatin-ifosfamide-gemcitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin is a platinum-based alkylating agent that cross-links DNA strands, preventing replication. Ifosfamide is an alkylating agent that also damages DNA through covalent bonding. Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, disrupting synthesis. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells.","oneSentence":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:05.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lung cancer (non-small cell lung cancer)"},{"name":"Potentially other solid tumors under investigation"}]},"trialDetails":[{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT03034304","phase":"PHASE1","title":"A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"HRYZ Biotech Co.","startDate":"2017-02-22","conditions":"Advanced Solid Tumors","enrollment":105},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06204614","phase":"EARLY_PHASE1","title":"Drug Screening Using IMD in Bladder Cancer","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2024-02-14","conditions":"Muscle Invasive Bladder Urothelial Carcinoma","enrollment":18},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT04342936","phase":"PHASE3","title":"Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-17","conditions":"Classical Hodgkin Lymphoma","enrollment":56},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02533700","phase":"PHASE2","title":"CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2015-09","conditions":"Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma","enrollment":106},{"nctId":"NCT03623087","phase":"PHASE3","title":"SIMPLE Chemotherapy for NK Lymphoma/Leukaemia","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-07-01","conditions":"Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin T-cell Lymphoma, Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":68},{"nctId":"NCT03071822","phase":"PHASE4","title":"Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2017-02-24","conditions":"Peripheral T Cell Lymphoma","enrollment":50},{"nctId":"NCT02560441","phase":"PHASE2","title":"Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2015-09","conditions":"Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type","enrollment":""},{"nctId":"NCT00920153","phase":"PHASE3","title":"Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma","status":"TERMINATED","sponsor":"French Innovative Leukemia Organisation","startDate":"2008-05","conditions":"Lymphoma","enrollment":442},{"nctId":"NCT01501136","phase":"PHASE4","title":"Treatment of Natural Killer/T Cell Lymphoma-I/II","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2011-01","conditions":"Nasal and Nasal-type NK/T-cell Lymphoma","enrollment":200},{"nctId":"NCT01501149","phase":"PHASE4","title":"Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2011-01","conditions":"Nasal and Nasal-type NK/T-cell Lymphoma","enrollment":80},{"nctId":"NCT02471027","phase":"","title":"The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Yu mei Wu","startDate":"2015-06","conditions":"Cervical Cancer","enrollment":1000},{"nctId":"NCT00673179","phase":"NA","title":"Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Osteosarcoma","enrollment":7},{"nctId":"NCT00003159","phase":"PHASE3","title":"Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1997-08","conditions":"Lung Cancer","enrollment":600},{"nctId":"NCT00003105","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"1997-09","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter","enrollment":30},{"nctId":"NCT00622349","phase":"PHASE3","title":"Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"European Lung Cancer Working Party","startDate":"2004-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":707},{"nctId":"NCT00551122","phase":"PHASE1, PHASE2","title":"Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2006-11","conditions":"Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":23},{"nctId":"NCT00080795","phase":"PHASE2","title":"Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-07","conditions":"Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer","enrollment":65},{"nctId":"NCT00148395","phase":"PHASE3","title":"Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.","status":"COMPLETED","sponsor":"Aktion Bronchialkarzinom e.V.","startDate":"2002-06","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":280},{"nctId":"NCT00173862","phase":"PHASE2","title":"Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2000-05","conditions":"Transitional Cell Carcinoma","enrollment":18},{"nctId":"NCT00127049","phase":"PHASE2","title":"Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors","status":"UNKNOWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2004-12","conditions":"Germ Cell Tumor","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cisplatin, Ifosfamide, Gemcitabine","genericName":"Cisplatin, Ifosfamide, Gemcitabine","companyName":"European Lung Cancer Working Party","companyId":"european-lung-cancer-working-party","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses three cytotoxic agents to damage cancer cell DNA and inhibit cell division. Used for Lung cancer (non-small cell lung cancer), Potentially other solid tumors under investigation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}